Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.

International journal of molecular sciences - 27 May 2021

Bonaldi Elisa, Gargiuli Chiara, De Cecco Loris, Micali Arianna, Rizzetti Maria Grazia, Greco Angela, Borrello Maria Grazia, Minna Emanuela

Abstract excerpt

BRAFV600E is the most frequent oncogenic mutation identified in papillary thyroid cancer (PTC). In PTC patients who do not respond to standard treatment, BRAF inhibitors are currently tested as alternative strategies. However, as observed for other targeted therapies, patients eventually develop drug resistance. The mechanisms of BRAF inhibitors response are still poorly understood in a thyroid cancer (TC)...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Computational Biology
Share to Dose-Response Relationship, Drug

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to ras Proteins

Share to Thyroid Neoplasms

Share to Transcriptome

Source

Open in PubMed Open full text

Identifiers

PMID: 34072194
DOI: 10.3390/ijms22115744
PMCID: PMC8198461

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF Inhibitors Induce Feedback Activation of RAS Pathway in Thyroid Cancer Cells.PMID 34072194Read ↗

BRAF Inhibitors in Thyroid Cancer: Clinical Impact, Mechanisms of Resistance and Future PerspectivesSemantic proximity Read ↗

BRAF mutations in thyroid cancer.Semantic proximity Read ↗

Targeting BRAF in thyroid cancer.Semantic proximity Read ↗

Role of BRAF in thyroid oncogenesis.Semantic proximity Read ↗

The role of BRAF in the pathogenesis of thyroid carcinoma.Semantic proximity Read ↗

Role of the ETV5/p38 signaling axis in aggressive thyroid cancer cellsSemantic proximity Read ↗

BRAF mutations in papillary thyroid carcinoma and emerging targeted therapies (review).Semantic proximity Read ↗

Synergistic Effect of Metformin and Vemurufenib (PLX4032) as a Molecular Targeted Therapy in Anaplastic Thyroid Cancer – An In Vitro StudySemantic proximity Read ↗

The BRAFV600E mutation: what is it really orchestrating in thyroid cancer?Semantic proximity Read ↗

Role of B-Raf(V600E) in differentiated thyroid cancer and preclinical validation of compounds against B-Raf(V600E).Semantic proximity Read ↗

MAPK pathway inhibitors enhance radioiodine sensitivity in anaplastic thyroid carcinoma through promoting NIS expression and ARF4-mediated NIS membrane transportSemantic proximity Read ↗

[Intracellular signaling mechanisms in thyroid cancer].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.